Antiplatelet therapies for the treatment of cardiovascular disease.
Antiplatelet therapy has been successful in reducing mortality and morbidity in acute myocardial infarction. Recent advances in understanding the molecular basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity. This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.
Michelson
Alan D
AD
Center for Platelet Research Studies, Children's Hospital Boston, Karp 08213, 300 Longwood Avenue, Boston, Massachusetts 02115-5737, USA. alan.michelson@childrens.harvard.edu
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D002986:Clinical Trials as Topic; D015195:Drug Design; D015507:Drugs, Investigational; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D013927:Thrombosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
D015507:Drugs, Investigational; D010975:Platelet Aggregation Inhibitors